News | News By Subject | News by Disease News By Date | Search News

Mesothelioma News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
This Year’s Top 10 Disappointing Clinical Trials—So Far!     7/6/2016
AstraZeneca PLC (AZN)'s Closely-Watched Mesothelioma Drug Fails Mid-Stage Study     2/29/2016
Verastem (VSTM) Stops Study of Experimental Cancer Therapy; Stock Plunges     9/29/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Alfacell (ACEL) Confirms 316 Patient Deaths in the Confirmatory Phase IIIb Trial of ONCONASE     4/2/2008
Cambridge Antibody Technology Group PLC  (CATG) Announces Acquisition of Oncology Product Candidate From Enzon Pharmaceuticals, Inc. (ENZN)     7/27/2006
Alfacell (ACEL) Drug Trial Ahead of Schedule; Revises Guidance On Patient Enrollment For The ONCONASE Confirmatory Phase IIIb Clinical Trial In Unresectable Malignant Mesothelioma     1/30/2006
Eli Lilly and Company (LLY) Release: Alimta(R) Receives CHMP Positive Opinion For Two Cancer Indications     6/24/2004

News from Around the Web

Press Releases
Five Prime (FPRX) Announces Updated Data In Mesothelioma Patients From Ongoing Phase Ib Trial Of FP-1039 At ESMO 2017 Congress     9/11/2017
Aduro Biotech (ADRO) Announces First Patient Dosed In Phase II Clinical Trial Of CRS-207 In Combination With KEYTRUDA® (Pembrolizumab) For The Treatment Of Patients With Previously Treated Malignant Pleural Mesothelioma     6/29/2017
Boehringer Ingelheim Release: Encouraging Phase II Survival Data For Oral Nintedanib In Malignant Pleural Mesothelioma Presented At ASCO 2017     6/5/2017
Aduro Biotech (ADRO) Announces Clinical Collaboration With Merck & Co. (MRK) To Evaluate The Combination Of Aduro’s CRS-207 With Merck's KEYTRUDA (Pembrolizumab) For The Treatment Of Mesothelioma     5/17/2017
Boehringer Ingelheim Release: Nintedanib Granted Orphan Drug Designation For Treatment Of Mesothelioma     12/15/2016
Boehringer Ingelheim Release: Clinically Meaningful Data For Oral Nintedanib In Mesothelioma Presented At World Conference On Lung Cancer     12/7/2016
Bayer (BAY) is Pumped Up About Its Potential Cancer Blockbuster But Investors are Skeptical     10/18/2016
SELLAS Life Sciences Group Receives FDA Fast Track Designation Of Galinpepimut-S For The Treatment Of Malignant Pleural Mesothelioma     9/19/2016
ASCO2016: SELLAS Life Sciences Group Announces Exciting Results For Galinpepimut-S, The Company's WT1 Vaccine, In Patients With Acute Myeloid Leukemia (AML) And Malignant Pleural Mesothelioma (MPM), As Presented At The 2016 ASCO Annual Meeting     6/6/2016
SELLAS Life Sciences Group Announces Upcoming Presentation Of Phase 2 Clinical Results For WT1 Cancer Vaccine At The 2016 ASCO Annual Meeting     5/24/2016
Bayer (BAY) To Showcase Latest Oncology Research At ASCO 2016     5/19/2016
Epizyme (EPZM) Announces FDA Acceptance Of Investigational New Drug Application For Tazemetostat In Mesothelioma     5/4/2016
107th Annual Meeting Of AACR: Bayer (BAY) To Present New Data On Advancing Oncology Portfolio     4/13/2016
SELLAS Life Sciences Group Receives A Favorable Opinion For European Orphan Drug Designations For WT1 Cancer Vaccine (galinpepimut-S) For The Treatment Of Acute Myeloid Leukemia And For Malignant Pleural Mesothelioma     4/5/2016
SELLAS Life Sciences Announces FDA Orphan Drug Designation For WT1 Cancer Vaccine In Patients With Malignant Pleural Mesothelioma     2/29/2016